These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 26061272)
1. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? Ciliberto D; Staropoli N; Caglioti F; Gualtieri S; Fiorillo L; Chiellino S; De Angelis AM; Mendicino F; Botta C; Caraglia M; Tassone P; Tagliaferri P Cancer Biol Ther; 2015; 16(8):1148-59. PubMed ID: 26061272 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for advanced gastric cancer. Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174 [TBL] [Abstract][Full Text] [Related]
7. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731 [TBL] [Abstract][Full Text] [Related]
8. The role of targeted agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials. Wang CW; Fang XH Eur Rev Med Pharmacol Sci; 2016 May; 20(9):1725-32. PubMed ID: 27212163 [TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases. Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. Qi YT; Hou Y; Qi LC Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164 [TBL] [Abstract][Full Text] [Related]
11. A systematic review of dual targeting in HER2-positive breast cancer. Kümler I; Tuxen MK; Nielsen DL Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156 [TBL] [Abstract][Full Text] [Related]
12. The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer. Li H; Zhai Q; Yu B J Cancer Res Ther; 2018; 14(Supplement):S218-S223. PubMed ID: 29578177 [TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
14. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review. Zou K; Yang S; Zheng L; Yang C; Xiong B BMC Cancer; 2016 Sep; 16(1):737. PubMed ID: 27633381 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Funakoshi T; Latif A; Galsky MD Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273 [TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Luo HQ; Han L; Jiang Y Asian Pac J Cancer Prev; 2014; 15(13):5343-8. PubMed ID: 25040999 [TBL] [Abstract][Full Text] [Related]
18. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402 [TBL] [Abstract][Full Text] [Related]
19. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590 [TBL] [Abstract][Full Text] [Related]
20. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]